Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients

BACKGROUND: Imatinib mesylate is a molecularly targeted tyrosine kinase inhibitor drug. It is effectively used in the treatment of chronic myeloid leukemia (CML) patients. However, development of resistance to imatinib mesylate as a result of BCR‐ABL dependent and BCR‐ABL independent mechanisms has...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Rep (Hoboken)
Hlavní autoři: Elias, Marjanu Hikmah, Azlan, Husin, Sulong, Sarina, Baba, Abdul Aziz, Ankathil, Ravindran
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7941502/
https://ncbi.nlm.nih.gov/pubmed/32721103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cnr2.1111
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky